OyaGen is focused on the discovery and development of therapeutics for the treatment of HIV. The Company has identified several unique druggable targets on HIV which attack the virus and/or strengthen the innate cell defense. Successful development of drugs that address these targets could offer patients first-in-class alternatives to current HIV therapies and bring the Company attractive potential financial returns. Having its origins in the science of RNA and DNA editing enzymes, their interactions and their regulation through the academic work of the Firm's founder and Senior Management, OyaGen, Inc. holds Intellectual Property (IP) licensed from Thomas Jefferson University, the University of Rochester, Oregon Health Sciences Center and Vybion Inc. The Company itself also holds a useful IP inventory.
